Mental Health
Hear the perspectives of people living with cancer on the topic of mental health.
Пошук
Saving Lives
The Angels initiative honours nurses saving lives one grandpa at a time
How do I treat mild to moderate renal impairment with Pradaxa®
.
Introduction to head-to-head trials
Introduction to head-to-head trials
BI Access to Healthcare Strategy_Availability
Boehringer Ingelheim aspires to be a leader in ensuring improved access by delivering More Health to humans, animals and communities around the world. Read more about our holistic approach, based on partnerships and local empowerment.
Berodual®
Prevention and treatment of symptoms in chronic obstructive airway disorders with reversible airflow limitation such as bronchial asthma and especially chronic bronchitis with or without emphysema.
Combivent® Respimat®
A combination of a short-acting anticholinergic and beta-adrenergic for the management of reversible bronchospasms associated with obstructive airway diseases in patients requiring more than one bronchodilator.
Glyxambi®
Treatment of type 2 diabetes mellitus to improve glycaemic control in adults when treatment with both empagliflozin and linagliptin is appropriate (US).
Spiriva®
Maintenance treatment of patients with COPD (including chronic bronchitis and emphysema), maintenance treatment of associated dyspnoea and for prevention of exacerbations.
MicardisPlus®
US: Treatment of hypertension alone or with other antihypertensive agents, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. Not indicated for
Компанія «Берінгер Інгельхайм» (Boehringer Ingelheim) придбала компанію «Саїба Енімал Хелс» (Saiba Animal Health), поповнивши свої спроможності науково-дослідних розробок у галузі ветеринарії інноваційною технологічною платформою
Компанія «Берінгер Інгельхайм» (Boehringer Ingelheim) придбала компанію «Саїба Енімал Хелс» (Saiba Animal Health), поповнивши свої спроможності науково-дослідних розробок у галузі ветеринарії інноваційною технологічною платформою
Jentadueto®
Treatment of type 2 diabetes mellitus to improve glycaemic control in adults when treatment with metformin does not lead to sufficient control or when patients are treated with trajenta® (linagliptin) and metformin.
Synjardy®
Treatment of type 2 diabetes mellitus to improve glycaemic control in adults when treatment with metformin does not lead to sufficient control or when patients are treated with jardiance® (empagliflozin) and metformin.
COVID-19 IMI2–Call 21
CARE launched to accelerate therapy development against COVID-19 and future coronavirus threats.
Trajenta®
Treatment of type 2 diabetes mellitus to improve glycaemic control in adults, used in monotherapy (if metformin is not tolerated or contraindicated) or in combination therapy.
Twynsta®
Treatment of hypertension alone or with other antihypertensive agents. As initial therapy in patients likely to need multiple antihypertensive agents to achieve their blood pressure goals (USA). Add-on therapy in adult patients with not adequately co
Spiriva® Respimat®
An add-on maintenance treatment in adult patients with asthma who are currently treated with the maintenance combination of inhaled corticosteroids.
COVID-19 Q&A for people with diabetes
QA Diabetes
Let’s meet the challenge
Together with our partners around the world, we are working on new and innovative solutions for unmet medical need in animal health.
Alesion®
Prophylactic treatment of patients with bronchial asthma. Prophylaxis and symptomatic treatment of allergic rhinitis.
Berotec®
Symptomatic treatment of acute asthma attacks. Prophylaxis of exercise-induced asthma bronchiale. Symptomatic treatment of allergic and non-allergic asthma bronchiale and other conditions with reversible airway narrowing, e.g. chronic obstructive bro
Advice to Fellow Patients
People living with cancer share their advice for fellow patients, from checking information sources to living in the present moment.
Spiolto® Respimat®
Maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD).
Micardis®
Treatment of hypertension. For the reduction of the risk of myocardial infarction (heart attack), stroke or death from cardiovascular (CV) causes in patients 55 years of age or older at high risk of developing major CV events who are unable to take A
LUX-Lung 7 & 8 Trials
.